Search Results - "Lyandres, J"

SP005 Rationale of the design of the I-SPY trial by DeMichele, A, Yee, D, Hylton, N, Vant'Veer, L, Symmons, W.F, Perlmutter, J, Lyandres, J, Davis, S, Buxton, M, Berry, D, Esserman, L

Get full text

Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL by Rugo, HS, Olopade, O, DeMichele, A, van 't Veer, L, Buxton, M, Hylton, N, Yee, D, Chien, AJ, Wallace, A, Lyandres, J, Davis, S, Sanil, A, Berry, D, Esserman, L

“…Abstract Background: I-SPY 2 is a multicenter, phase 2 screening trial using adaptive randomization within biomarker subtypes to evaluate a series of novel…”
Get full text

Abstract P2-11-02: A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL by Paoloni, M, Lyandres, J, Buxton, MB, Berry, DA, Esserman, LJ, DeMichele, A, Yee, D

“…Abstract Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate a series of…”
Get full text

Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial by Forero, A, Yee, D, Buxton, MB, Symmans, WF, Chien, AJ, Boughey, JC, Elias, AD, DeMichele, A, Moulder, S, Minton, S, Kaplan, HG, Albain, KS, Wallace, AM, Haley, BB, Isaacs, C, Korde, LA, Nanda, R, Lang, JE, Kemmer, KA, Hylton, NM, Paoloni, M, van't Veer, L, Lyandres, J, Perlmutter, J, Hogarth, M, Yau, C, Sanil, A, Berry, DA, Esserman, LJ

“…Abstract Background:Pathologic complete response(pCR) after neoadjuvant therapy is an established prognostic biomarker for high-risk breast cancer(BC)…”
Get full text

Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial by Yee, D, Paoloni, M, van't Veer, L, Sanil, A, Yau, C, Forero, A, Chien, AJ, Wallace, AM, Moulder, S, Albain, KS, Kaplan, HG, Elias, AD, Haley, BB, Boughey, JC, Kemmer, KA, Korde, LA, Isaacs, C, Minton, S, Nanda, R, DeMichele, A, Lang, JE, Buxton, MB, Hylton, NM, Symmans, WF, Lyandres, J, Hogarth, M, Perlmutter, J, Esserman, LJ, Berry, DA

“…Abstract Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate novel agents when…”
Get full text

Phase I study of sunitinib in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer by Lyandres, J, Melisko, M, Moasser, M, Goga, A, Park, JW, Rugo, HS

“…Abstract Abstract #4119 Background
 Antiangiogenic therapy targeting VEGF with bevacizumab in combination with taxanes is effective in the treatment of…”
Get full text

Phase I study of sunitinib (S) in combination with metronomic dosing of cyclophosphamide and methotrexate (CM) in patients with metastatic breast cancer (MBC) by Lyandres, J., Moasser, M. M., Melisko, M., Goga, A., Park, J. W., Rugo, H. S.

“…Abstract only…”
Get full text

Phase II study of irinotecan (irin) and temozolomide (TMZ) in breast cancer patients with brain metastases that have progressed after stereotactic radiosurgery (SRS) or whole brain radiation (WBRT) by Melisko, M., Lyandres, J., Scott, J., Park, J. W., Rugo, H. S.

“…Abstract only…”
Get full text

Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC) by Dickler, M, Franco, S, Stopeck, A, Ma, W, Nulsen, B, Lyandres, J, Melisko, M, Lahiri, S, Arbushites, M, Koehler, M, Rugo, HS

“…Abstract Abstract #3133 Background:
 HER2 overexpression has been shown to upregulate VEGF expression in pre-clinical breast cancer models. Overexpression of…”
Get full text

Circulating tumor cell and endothelial cell data from a phase II evaluation of lapatinib and bevacizumab in HER2-overexpressing metastatic breast cancer by Rugo, HS, Dickler, M, Franco, S, Stopeck, A, Lyandres, J, Melisko, M, Lahiri, S, Arbushites, M, Koehler, M, Lin, Y, Scott, J, Park, J

“…Abstract Abstract #3154 Background: Overexpression of both HER2 and VEGF is associated with worse outcome than overexpression of either receptor alone. In…”
Get full text

A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC) by Rugo, H. S., Franco, S., Munster, P., Stopeck, A., Ma, W., Lyandres, J., Lahiri, S., Arbushites, M., Koehler, M., Dickler, M. N.

“…Abstract only…”
Get full text

Utility of bortezomib retreatment among patients with refractory multiple myeloma by Wolf, J. L., Leblanc MT, A. L., Battleman, D. S., Davis, B., Lyandres, J. R., Walters, I. B.

“…Abstract only 17549 Background: Bortezomib (VELCADE; Vc) has emerged as the standard of care for patients with relapsed or refractory multiple myeloma (MM)…”
Get full text

Abstract P1-14-03: The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL by Albain, KS, Leyland-Jones, B, Symmans, F, Paoloni, M, van 't Veer, L, DeMichele, A, Buxton, M, Hylton, N, Yee, D, Lyandres Clennell, J, Yau, C, Sanil, A, Berry, D, Esserman, L

“…Abstract Background: I-SPY 2 is a multicenter phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate a series of novel…”
Get full text